Baidu
map

Cell Repo:FoxM1与乳腺癌发生的关系

2012-06-18 mili 生物谷

FoxM1(Forkhead box protein M1)是一个癌蛋白,在乳腺癌中,FoxM1高表达总是与较差的愈后和细胞分化不完全有关。但FoxM1是如何调节乳腺细胞分化的目前尚不清楚。 本文的研究者发现,FoxM1以转录抑制因子的身份,来调节管腔上皮祖细胞分化的。在乳腺再生的过程中高表达FoxM1会导致管腔上皮祖细胞数量增多和乳腺导管形态紊乱。与之相反,敲减FoxM1则会导致乳腺细胞的过度

FoxM1(Forkhead box protein M1)是一个癌蛋白,在乳腺癌中,FoxM1高表达总是与较差的愈后和细胞分化不完全有关。但FoxM1是如何调节乳腺细胞分化的目前尚不清楚。

本文的研究者发现,FoxM1以转录抑制因子的身份,来调节管腔上皮祖细胞分化的。在乳腺再生的过程中高表达FoxM1会导致管腔上皮祖细胞数量增多和乳腺导管形态紊乱。与之相反,敲减FoxM1则会导致乳腺细胞的过度分化。研究表明,FoxM1是通过促进GATA3启动子区甲基化,从而抑制GATA-3转录来达到这一效果的。而GATA-3是一个转录因子,其作用正是维持乳腺细胞的导管分化。

这一研究成果说明了FoxM1是调节乳腺细胞分化的关键因子,并为乳腺癌的治疗提供了一个好的靶标。

doi:10.1016/j.celrep.2012.05.005

PMC:
PMID:

FoxM1 Regulates Mammary Luminal Cell Fate

Janai R. Carr, Megan M. Kiefer, Hyun Jung Park, Jing Li, Zebin Wang, Joel Fontanarosa, Danielle DeWaal, Dragana Kopanja, Elizaveta V. Benevolenskaya, Grace Guzman, Pradip Raychaudhuri

Elevated expression of FoxM1 in breast cancer correlates with an undifferentiated tumor phenotype and a negative clinical outcome. However, a role for FoxM1 in regulating mammary differentiation was not known. Here, we identify another function of FoxM1, the ability to act as a transcriptional repressor, which plays an important role in regulating the differentiation of luminal epithelial progenitors. Regeneration of mammary glands with elevated levels of FoxM1 leads to aberrant ductal morphology and expansion of the luminal progenitor pool. Conversely, knockdown of FoxM1 results in a shift toward the differentiated state. FoxM1 mediates these effects by repressing the key regulator of luminal differentiation, GATA-3. Through association with DNMT3b, FoxM1 promotes methylation of the GATA-3 promoter in an Rb-dependent manner. This study identifies FoxM1 as a critical regulator of mammary differentiation with significant implications for the development of aggressive breast cancers.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958766, encodeId=b4371958e6692, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Mar 13 19:59:00 CST 2013, time=2013-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642803, encodeId=fd39164280386, content=<a href='/topic/show?id=165be622f0' target=_blank style='color:#2F92EE;'>#FOXM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7622, encryptionId=165be622f0, topicName=FOXM1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36ca23025609, createdName=ms3046638856685384, createdTime=Mon Feb 04 13:59:00 CST 2013, time=2013-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868534, encodeId=fa711868534dd, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Mar 10 18:59:00 CST 2013, time=2013-03-10, status=1, ipAttribution=)]
    2013-03-13 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958766, encodeId=b4371958e6692, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Mar 13 19:59:00 CST 2013, time=2013-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642803, encodeId=fd39164280386, content=<a href='/topic/show?id=165be622f0' target=_blank style='color:#2F92EE;'>#FOXM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7622, encryptionId=165be622f0, topicName=FOXM1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36ca23025609, createdName=ms3046638856685384, createdTime=Mon Feb 04 13:59:00 CST 2013, time=2013-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868534, encodeId=fa711868534dd, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Mar 10 18:59:00 CST 2013, time=2013-03-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958766, encodeId=b4371958e6692, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Mar 13 19:59:00 CST 2013, time=2013-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642803, encodeId=fd39164280386, content=<a href='/topic/show?id=165be622f0' target=_blank style='color:#2F92EE;'>#FOXM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7622, encryptionId=165be622f0, topicName=FOXM1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36ca23025609, createdName=ms3046638856685384, createdTime=Mon Feb 04 13:59:00 CST 2013, time=2013-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868534, encodeId=fa711868534dd, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Mar 10 18:59:00 CST 2013, time=2013-03-10, status=1, ipAttribution=)]

相关资讯

2010年中国科技论文统计出炉,生物医药领域表现不俗

中国科技信息研究所(下称中信所)12月2日对外发布了2010年中国科技论文(下称国际论文)统计结果。 2010年,我国机构作者为第一作者发表的国际论文共12.15万篇,其中23968篇论文的被引用次数高于学科均线,即其论文发表后的影响超过其所在学科的一般水平,也就是说占我国论文总数的19.7%的论文表现不俗,该比例较2009年的15.5%上升了4.2个百分点。我国表现不俗的论文 81.6%由

Cancer Cell:LKB1基因失活驱动黑色素瘤转移

为什么某些癌症会迅速蔓延到其他器官,而某些人却不发生转移?Norman Sharpless博士,领导的UNC研究团队近日确定了一个关键基因开关,该基因决定了一种致命的皮肤癌--黑色素瘤是否会发生转移扩散。 黑色素瘤(melanoma)又称恶性黑色素瘤,是一种能产生黑色素的高度恶性肿瘤。大多见于30岁以上成年人,发生于皮肤、粘膜和内脏器官。黑色素瘤的预后多数较差,晚期可有淋巴道及血液转移。黑色素瘤

Cancer Cell:弥散性大B细胞淋巴瘤协同性化疗新进展

6月12日,Cancer Cell杂志报道了弥散性大B细胞淋巴瘤化学协同治疗的最新进展。 癌基因突变的知识,可催生靶向性杀死癌细胞而避免正常细胞受害的治疗手段。来那度胺在弥散性大B细胞淋巴瘤(DLBCL)的活化B细胞样(ABC)亚型中是一种活性药物。由于ABC DLBCL细胞中存在MYD88癌基因,来那度胺可通过促进干扰素β (IFNβ)的产生来杀死这些癌细胞。 来那度胺以cereblon依赖

Cell Mol Life Sci:科学家发现新的炎症治疗目标

称为初级纤毛的微小细胞器是抗击炎症的关键,伦敦玛丽大学的科学家们发现了一种新的抗击炎症的治疗目标。 相关研究论文发表在Cellular and Molecular Life Sciences杂志上,研究人员发现称为初级纤毛的微小细胞器对调节炎症反应很重要。这一发现可能为百万计患有关节炎的人带来潜在的新的治疗方法。 Martin Knight博士说:“虽然初级纤毛已经发现了有一个多世纪前,但我们

Cancer Cell:去泛素化酶调节肝炎、纤维化和癌变

6月12日,Cancer Cell杂志报道了去泛素化酶,圆柱瘤病(CYLD)肿瘤抑制因子的失活可引发肝细胞的凋亡、炎症、纤维化和癌症。圆柱瘤病(CYLD)肿瘤抑制因子通过去泛素化上游因子,抑制NFκB和有丝分裂原活化蛋白激酶(MAPK)活化途径。 本研究显示,肝特异性阻断CYLD通过自发的或慢性激活TGF-β活化激酶1(TAK1)和c-Jun N末端激酶(JNK)触发了肝门静脉周边区域肝细胞的死

Baidu
map
Baidu
map
Baidu
map